• 作者：Marta Cuadros^a ; ^b ; ^{cuadroslujan@yahoo.es} ; ^{marta.cuadros.ext@juntadeandalucia.es} ; Aurora Llanos^a
• 关键词：MammaPrint® ; C&aacute ; ncer de mama ; Perfil de expresió ; n gené ; tica ; An&aacute ; lisis de secuencia de oligonucleó ; tidos en matrices
• 刊名：Medicina Cl铆nica
• 出版年：2011
• 期刊代码：pca254_00257753
• 类别：med
• 出版时间：21 May 2011
• 卷：136
• 期：14
• 页码：627-632
• 文件大小：243 K

class="h4">Background and objective

MammaPrint^庐 is a micromatrix based test and the result classifies analyzed tumors as low or high risk for recurrence of breast carcinoma. By analyzing the individual activity of these genes, MammaPrint^庐 estimates the response to chemotherapy and/or predicts the outcome of the breast neoplasia. We aimed to assess the clinical and analytical validity of MammaPrint^庐 that determines individual risk of relapse of breast cancer.

class="h4">Materials and methods

Systematic review of the literature using a structured database search (MedLine, CRD, ECRI Institute, Cochrane Library) and Tripdatabase metasearch. The criteria for selecting report for inclusion were the following: population (breast carcinoma), intervention (MammaPrint^庐 versus medical outcome systems and molecular techniques), and analytic (reproducibility and validity of the method) and/or clinical (the ability to predict mortality among patients, metastasis-free time) results.

class="h4">Results

We found 75 documents. After eliminating the studies that did not satisfied the inclusion criteria, 10 studies were evaluated. Only one paper analyzed MammaPrint^庐 reproducibility, indicating reliability and validity of this methodology. The risk of distant metastasis associated with poor prognosis signature versus good prognosis, ranged from 5.7 (IC95%=1.6鈥?0) for 5.8 year follow-up to 2.32 (IC95%=1.35鈥?.00) for 13.6 year follow up. MammaPrint^庐 was identified as an independent predictor of risk for metastasis, as well as the tumor diameter and non-use of chemotherapy.

class="h4">Conclusions

MammaPrint^庐 test could bring benefits to the diagnosis and treatment of breast cancer patients but there was no evidence to conclude its clinical usefulness in patients who predicts an a priori advantage to chemotherapy.